• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

用于靶向癌症治疗的细胞毒性铁螯合剂的糖苷酶激活前药。

Glycosidase-activated prodrugs of a cytotoxic iron chelator for targeted cancer therapy.

作者信息

Tomar Debashish, Steinbrueck Axel, Sedgwick Adam C, Levine Matthew S, Sessler Jonathan L, Metzler-Nolte Nils

机构信息

Faculty of Chemistry and Biochemistry, Inorganic Chemistry I - Bioinorganic chemistry, Ruhr-University Bochum Universitaetsstrasse 150 44801 Bochum Germany

Department of Chemistry, University of Texas at Austin 105 E 24th street A5300 Austin TX 78712-1224 USA.

出版信息

RSC Med Chem. 2025 Jun 19. doi: 10.1039/d5md00232j.

DOI:10.1039/d5md00232j
PMID:40547260
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12177571/
Abstract

New glycoside-prodrugs based on the iron chelator deferasirox were designed. Selective enzymatic activation by glycosidases was observed within 24 hours, accompanied by cancer cell-selective cytotoxicity. Notably, derivative 3a, bearing a β-d-galactose moiety, showed promising selective activity against galactosidase overexpressing OvCar-3 cells (IC 9.1 ± 1.6 μM) while maintaining low activity against fibroblast control GM5756 cells (IC > 100 μM).

摘要

设计了基于铁螯合剂地拉罗司的新型糖苷前药。在24小时内观察到糖苷酶的选择性酶促活化,并伴有癌细胞选择性细胞毒性。值得注意的是,带有β - d - 半乳糖部分的衍生物3a对过表达半乳糖苷酶的OvCar - 3细胞显示出有前景的选择性活性(IC 9.1 ± 1.6 μM),而对成纤维细胞对照GM5756细胞的活性较低(IC > 100 μM)。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/401b/12377071/46d4bc08c210/d5md00232j-f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/401b/12377071/f7a649e6d20f/d5md00232j-f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/401b/12377071/e5c3208f5f8a/d5md00232j-s1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/401b/12377071/30ea319e41b3/d5md00232j-f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/401b/12377071/598def158a6b/d5md00232j-f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/401b/12377071/46d4bc08c210/d5md00232j-f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/401b/12377071/f7a649e6d20f/d5md00232j-f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/401b/12377071/e5c3208f5f8a/d5md00232j-s1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/401b/12377071/30ea319e41b3/d5md00232j-f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/401b/12377071/598def158a6b/d5md00232j-f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/401b/12377071/46d4bc08c210/d5md00232j-f4.jpg

相似文献

1
Glycosidase-activated prodrugs of a cytotoxic iron chelator for targeted cancer therapy.用于靶向癌症治疗的细胞毒性铁螯合剂的糖苷酶激活前药。
RSC Med Chem. 2025 Jun 19. doi: 10.1039/d5md00232j.
2
Design, synthesis, and biological evaluation of pyrazole-based combretastatin A-4 analogues as potential cytotoxic agents.基于吡唑的康普他汀A-4类似物作为潜在细胞毒性剂的设计、合成及生物学评价
Bioorg Chem. 2025 Jun 16;163:108691. doi: 10.1016/j.bioorg.2025.108691.
3
Deferasirox for managing iron overload in people with thalassaemia.地拉罗司用于治疗地中海贫血患者的铁过载。
Cochrane Database Syst Rev. 2017 Aug 15;8(8):CD007476. doi: 10.1002/14651858.CD007476.pub3.
4
Desferrioxamine mesylate for managing transfusional iron overload in people with transfusion-dependent thalassaemia.甲磺酸去铁胺用于治疗依赖输血的地中海贫血患者的输血性铁过载。
Cochrane Database Syst Rev. 2013 Aug 21;2013(8):CD004450. doi: 10.1002/14651858.CD004450.pub3.
5
Examining the 2-aryl-5-nitrobenzofuran-based hydrazones for anti-breast (MCF-7) cancer activity, potential to induce cell cycle arrest and inhibit receptor tyrosine kinases (VEGFR-2 & EGFR).研究基于2-芳基-5-硝基苯并呋喃的腙类化合物的抗乳腺癌(MCF-7)活性、诱导细胞周期停滞的潜力以及抑制受体酪氨酸激酶(VEGFR-2和EGFR)的能力。
Eur J Med Chem. 2025 Nov 15;298:118018. doi: 10.1016/j.ejmech.2025.118018. Epub 2025 Aug 4.
6
Novel quinazolin-4-one based derivatives bearing 1,2,3-triazole and glycoside moieties as potential cytotoxic agents through dual EGFR and VEGFR-2 inhibitory activity.新型喹唑啉-4-酮类衍生物,含有 1,2,3-三唑和糖苷片段,具有双重 EGFR 和 VEGFR-2 抑制活性,有望成为细胞毒性药物。
Sci Rep. 2024 Oct 23;14(1):24980. doi: 10.1038/s41598-024-73171-8.
7
Deferasirox for managing iron overload in people with thalassaemia.地拉罗司用于治疗地中海贫血患者的铁过载。
Cochrane Database Syst Rev. 2012 Feb 15(2):CD007476. doi: 10.1002/14651858.CD007476.pub2.
8
Gold nanocomposites in colorectal cancer therapy: characterization, selective cytotoxicity, and migration inhibition.用于结直肠癌治疗的金纳米复合材料:表征、选择性细胞毒性及迁移抑制
Naunyn Schmiedebergs Arch Pharmacol. 2025 Jan 29. doi: 10.1007/s00210-025-03839-z.
9
Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia.改善镰状细胞病或地中海贫血患者铁螯合疗法依从性的干预措施。
Cochrane Database Syst Rev. 2018 May 8;5(5):CD012349. doi: 10.1002/14651858.CD012349.pub2.
10
Development of novel quinazolinone-based compounds with anti-proliferative activity as dual STAT-3 and c-Src inhibitors: design, synthesis and molecular dynamic studies.新型喹唑啉酮类化合物作为双靶点STAT-3和c-Src抑制剂的抗增殖活性研究:设计、合成及分子动力学研究
Bioorg Chem. 2025 Aug;163:108753. doi: 10.1016/j.bioorg.2025.108753. Epub 2025 Jul 15.

本文引用的文献

1
Prodrugs in Oncology: Bioactivation and Impact on Therapeutic Efficacy and Toxicity.肿瘤学中的前药:生物活化及其对治疗效果和毒性的影响。
Int J Mol Sci. 2025 Jan 24;26(3):988. doi: 10.3390/ijms26030988.
2
Glycosidase activated prodrugs for targeted cancer therapy.糖基酶激活前药用于靶向癌症治疗。
Chem Soc Rev. 2022 Nov 28;51(23):9694-9716. doi: 10.1039/d2cs00379a.
3
Tuning the Solid- and Solution-State Fluorescence of the Iron-Chelator Deferasirox.调变铁螯合剂地拉罗司的固态和溶液荧光。
J Am Chem Soc. 2022 Apr 27;144(16):7382-7390. doi: 10.1021/jacs.2c01155. Epub 2022 Apr 14.
4
Synthesis of d-Galactose-Substituted Acylsilanes and Acylgermanes. Model Compounds for Visible Light Photoinitiators with Intriguing High Solubility.D-半乳糖取代的酰基硅烷和酰基锗烷的合成。具有高溶解性的可见光光引发剂的模型化合物。
Organometallics. 2021 May 10;40(9):1185-1189. doi: 10.1021/acs.organomet.0c00753. Epub 2021 Apr 27.
5
studies of deferasirox derivatives as potential organelle-targeting traceable anti-cancer therapeutics.研究去铁酮衍生物作为潜在的细胞器靶向追踪抗癌治疗药物。
Chem Commun (Camb). 2021 Jun 8;57(46):5678-5681. doi: 10.1039/d0cc08156f.
6
Deferasirox (ExJade): An FDA-Approved AIEgen Platform with Unique Photophysical Properties.地拉罗司(Exjade):具有独特光物理特性的美国 FDA 批准的聚集诱导发光剂平台。
J Am Chem Soc. 2021 Jan 27;143(3):1278-1283. doi: 10.1021/jacs.0c11641. Epub 2021 Jan 11.
7
Iron chelators in cancer therapy.癌症治疗中的铁螯合剂。
Biometals. 2020 Oct;33(4-5):201-215. doi: 10.1007/s10534-020-00243-3. Epub 2020 Aug 5.
8
Transition metal chelators, pro-chelators, and ionophores as small molecule cancer chemotherapeutic agents.过渡金属螯合剂、前螯合剂和离子载体作为小分子癌症化疗药物。
Chem Soc Rev. 2020 Jun 22;49(12):3726-3747. doi: 10.1039/c9cs00373h.
9
The Clinically Used Iron Chelator Deferasirox Is an Inhibitor of Epigenetic JumonjiC Domain-Containing Histone Demethylases.临床上使用的铁螯合剂地拉罗司是组蛋白去甲基化酶 JumonjiC 结构域包含物的抑制剂。
ACS Chem Biol. 2019 Aug 16;14(8):1737-1750. doi: 10.1021/acschembio.9b00289. Epub 2019 Jul 19.
10
Theranostic Nanodots with Aggregation-Induced Emission Characteristic for Targeted and Image-Guided Photodynamic Therapy of Hepatocellular Carcinoma.具有聚集诱导发光特性的治疗诊断一体化纳米点用于肝癌的靶向及影像引导光动力学治疗。
Theranostics. 2019 Feb 12;9(5):1264-1279. doi: 10.7150/thno.29101. eCollection 2019.